Trial Profile
Open-label Phase 1b, Dose-ranged, Single and Multiple Dose Study to assess Safety and Pharmacokinetics of TRO19622 in 6-25 year old Spinal Muscular Atrophy (SMA) patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Olesoxime (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacokinetics
- 01 Apr 2022 Status changed from not stated to completed.
- 21 Jun 2011 New trial record